Transplante de células-tronco hematopoéticas no diabete melito do tipo I

Voltarelli, Júlio César

doi:10.1590/s1516-84842004000100008

Cited by 13 publications

(14 citation statements)

References 6 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…É realizada então a coleta propriamente dita, que pode ser com placenta intrauterina ou extrauterina e mista, em qualquer tipo de parto (Brasil, 2004;Voltarelli, Pasquini & Ortega, 2009;Santos, Marti, Ribeiro, Conti & Barros, 2011).…”

Section: Conhecimentosunclassified

Producción científica de enfermería en el trasplante de células madre hematopoyéticas de sangre de cordón umbilical

Silva¹,

Azevedo²,

Nelson³

et al. 2018

cuid

View full text Add to dashboard Cite

Section: Conhecimentosunclassified

Producción científica de enfermería en el trasplante de células madre hematopoyéticas de sangre de cordón umbilical

Silva¹,

Azevedo²,

Nelson³

et al. 2018

cuid

View full text Add to dashboard Cite

“…[8][9] The conditioning phase can be highlighted among the decisive steps throughout the HSCT process, in which the patient receives chemotherapy and/or radiotherapy to cause medullary aplasia and induce immunosuppression with the purpose of avoiding rejection of the new grafted bone marrow. [10][11] At this stage, the patient suffers from symptomatologies arising from the administered drugs, and gastrointestinal disorders are common.…”

Section: Introductionmentioning

confidence: 99%

“…[11][12] At this stage, mucositis can be intensified causing pain and discomfort, making speech and swallowing difficult. These symptoms have disabling potential and weaken the patient, negatively interfering in their QoL.…”

Section: Introductionmentioning

confidence: 99%

Qualidade De Vida Nos Primeiros Seis Meses Pós-Transplante De Células-Tronco Hematopoéticas

Marques

Proença

Machado

et al. 2017

Texto contexto - enferm.

View full text Add to dashboard Cite

Objective: to evaluate the quality of life of adult patients with hematologic cancers undergoing hematopoietic stem cell transplantation in the first six months and comparing the transplant modalities.Method: an observational longitudinal study with 55 participants followed during pre-transplantation, after 100 days, and after 180 days in a reference teaching hospital for this treatment in Brazil. Two international instruments were used for the evaluation, both validated and translated into Portuguese (Brazil): The Quality of Life Questionnaire-Core 30 and the Functional Assessment Cancer Therapy-Bone Marrow Transplantation. Results:The results showed that the average age of the participants was 36 years old; 65% (n=36) had a diagnosis of leukemia, and 71% (n=39) underwent allogeneic transplantation. Regarding the Quality of Life Questionnaire-Core 30 instrument, social function and fatigue were significant results, while the functional well-being and treatment outcome evaluation index for the Functional Assessment Cancer Therapy-Bone Marrow Transplantation questionnaire had significant domains between the first and the second stage.Conclusions: despite transplantation being a complex and aggressive treatment, it can be noticed that patients generally perceive their quality of life as satisfactory throughout the therapeutic process. The findings of the study show that a significant portion (69% of patients) recover their quality of life after the first six months of treatment. DESCRIPTORS: QUALIDADE DE VIDA NOS PRIMEIROS SEIS MESES PÓS-TRANSPLANTE DE CÉLULAS-TRONCO HEMATOPOÉTICAS CALIDAD DE VIDA EN LOS PRIMEROS SEIS MESES POST-TRANSPLANTES DE CÉLULAS-TRONCO HEMATOPOÉTICAS RESUMENObjetivo: evaluar la calidad de vida de los pacientes adultos con cáncer hematológico sometidos al transplante de células madre hematopoyéticas en los primeros seis meses y comparar entre las modalidades de trasplante.Método: estudio observacional, longitudinal, con 55 participantes, acompañados en las etapas pre-trasplante, después de 100 días y después de 180 días, en un hospital de enseñanza, referencia en Brasil para este tratamiento. Para la evaluación se utilizaron dos instrumentos internacionales, ambos validados y traducidos a la lengua portuguesa (

show abstract

“…The Hematopoietic Stem Cell Transplantation (HSCT) is a treatment modality used more frequently for oncology and hematological diseases genetically inherited or acquired [1][2]. The HSCT may occur by autologous transplantation, when Hematopoietic Progenitor Cells (HPC) are from the patient; allogeneic when HPC come from donors with compatible Human Leukocyte Antigen (HLA), related when they are of the same family and not related if it is not from an inbred donor; or syngeneic transplantation, when HPC are from identical twins [3].…”

Section: Introductionmentioning

confidence: 99%

“…The graft-versus-host disease (GVHD) is presented as the main complication after HSCT, more frequently in allogeneic transplantations [1][2][3]. This can affect many organ systems and cause consequences to transplant patients, both in an acute form, in the first 100 days after HSCT as in the chronic form after this period [4].…”

Section: Introductionmentioning

confidence: 99%

Evidence For Dry Eye Treatment In Hematopoietic Stem Cells Post-Transplantation

Azevedo

Araújo²,

Costa³

et al. 2016

Int Arch Med

View full text Add to dashboard Cite

Introduction: Hematopoietic Stem Cell Transplantation (HSCT) is a treatment modality for oncology and hematological diseases genetically inherited or acquired. The morbidities and mortalities related to HSCT are evident in its different phases, such as the Graft Versus Host Disease especially on dry eye syndrome, one of the most complication of chronic phase, characterized as a multifactorial disease of the ocular surface. Several treatments may be directed to the dry eye and the consequences caused by it during the HSCT post-period.Objective: To reveal the treatments for dry eye in patients after HSCT period.Method: This is a literature integrative review performed by the SCOPUS databases, National Library of Medicine (PubMed); Web of Science and Cumulative Index to Nursing and Allied Heath Literature (CINAHL). Results:Of the 1,551 articles identified, there were 21 in the final sample. Regarding the treatments addressed, the most often used was found the cyclosporine 0.05%, followed by allogeneic and autologous drops. Conclusion:There was no consensus identified as the best type of treatment for these patients. However, it is known that depend mainly on clinical features of chronic graft-versus-host eye on the post-transplantation situation.

show abstract

Transplante de células-tronco hematopoéticas no diabete melito do tipo I

Cited by 13 publications

References 6 publications

Producción científica de enfermería en el trasplante de células madre hematopoyéticas de sangre de cordón umbilical

Producción científica de enfermería en el trasplante de células madre hematopoyéticas de sangre de cordón umbilical

Qualidade De Vida Nos Primeiros Seis Meses Pós-Transplante De Células-Tronco Hematopoéticas

Evidence For Dry Eye Treatment In Hematopoietic Stem Cells Post-Transplantation

Contact Info

Product

Resources

About